COMPANY PROFILE

Amber Bio

A biotechnology company developing a first-of-its-kind RNA writing platform using multi-kilobase edits to reach previously undruggable patient populations, pioneering new gene editing modalities for…

South San Francisco, United StatesFounded 2021Biotech & Life Sciences

Valuation $100–250M Last recorded · 2023

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Amber Bio

Amber Bio is a biotechnology company that has developed a platform for RNA editing. This platform allows for the editing of multi-kilobase RNA strands, which can be used to correct genetic mutations that cause diseases.

The company's technology is based on a deep understanding of RNA biology and machine learning. Amber Bio's platform has the potential to treat a wide range of diseases, including genetic disorders, cancer, and infectious diseases.

Amber Bio was founded in 2023 by a team of experienced scientists and entrepreneurs. The company has raised $26 million in seed financing from Playground Global and Andreessen Horowitz.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2021
Headquarters: South San Francisco, United States
Employees: 24
Open positions: None listed
Dealroom signal: 80.4/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SEED✓Equity / VC	Aug 2023	$26M	$104M	Hummingbird Ventures · Playground Global · Eli Lilly · Pillar VC	↗
SPINOUT✓Other financing	Dec 2021	$0	—	University of California, Berkeley	—

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Amber Bio website traffic

Latest recorded traffic for Amber Bio is 5.6K monthly website visits, up 124% over the last three months. Amber Bio's team grew 14.3% over the past year.

Latest monthly visits5.6K 3-month web change+124% 1-year team growth+14.3%

Monthly website visitsAug 2023–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
PRPrecirixCamelid-derived radiopharmaceuticals for targeted cancer therapy	Jette, Belgium	Operational	9	$130M	$352M
SPStrike PharmaDevelops a novel next generation Antibody-Drug Conjugate (ADC) technology, the ADAC technology	Uppsala kommun, Sweden	Operational
PTPROSION TherapeuticsPROSION Therapeutics is a drug development company with a proprietary platform that addresses highly unmet medical needs by unlocking undruggables	Cologne, Germany	Operational
OLOlgramInnovations from the sea to tackle antibiotic resistance \| Olgram	Paris, France	Operational
ATAsgard TherapeuticsSpin-off company from Lund University focusing on developing cancer immunotherapies based on cell fate reprogramming	Lund Municipality, Sweden	Operational
CTCARsgen TherapeuticsA leading immunotherapy company focused on the development of new chimeric antigen receptor	Xuhui District, China	Operational
ABAnnexon BiosciencesBiotech company, discovering and developing novel therapeutics for neurodegenerative and autoimmune disorders	San Francisco, United States	Operational
ELElasmogenNext generation therapeutic biologics company discovering and developing drugs	Aberdeen, United Kingdom	Operational